A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety,
tolerability, and pharmacokinetic profiles of botensilimab as monotherapy in participants
with advanced melanoma refractory to checkpoint inhibitor therapy.